Role of microRNAs in breast cancer

References

• Chalfie M, Horvitz HR, Sulston JE. Mutations that lead to reiterations in the cell lineages of C. elegans. Cell 1981; 24:59 - 69; http://dx.doi.org/10.1016/0092-8674(81)90501-8; PMID: 7237544
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843 - 54; http://dx.doi.org/10.1016/0092-8674(93)90529-Y; PMID: 8252621
   PubMed Web of Science ®Google Scholar
• Kim VN, Nam JW. Genomics of microRNA. Trends Genet 2006; 22:165 - 73; http://dx.doi.org/10.1016/j.tig.2006.01.003; PMID: 16446010
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281 - 97; http://dx.doi.org/10.1016/S0092-8674(04)00045-5; PMID: 14744438
   PubMed Web of Science ®Google Scholar
• Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A 2006; 103:4034 - 9; http://dx.doi.org/10.1073/pnas.0510928103; PMID: 16495412
   PubMed Web of Science ®Google Scholar
• Giraldez AJ, Mishima Y, Rihel J, Grocock RJ, Van Dongen S, Inoue K, et al. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science 2006; 312:75 - 9; http://dx.doi.org/10.1126/science.1122689; PMID: 16484454
   PubMed Web of Science ®Google Scholar
• Behm-Ansmant I, Rehwinkel J, Doerks T, Stark A, Bork P, Izaurralde E. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev 2006; 20:1885 - 98; http://dx.doi.org/10.1101/gad.1424106; PMID: 16815998
   PubMed Web of Science ®Google Scholar
• Eulalio A, Rehwinkel J, Stricker M, Huntzinger E, Yang SF, Doerks T, et al. Target-specific requirements for enhancers of decapping in miRNA-mediated gene silencing. Genes Dev 2007; 21:2558 - 70; http://dx.doi.org/10.1101/gad.443107; PMID: 17901217
   PubMed Web of Science ®Google Scholar
• Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005; 309:1573 - 6; http://dx.doi.org/10.1126/science.1115079; PMID: 16081698
   PubMed Web of Science ®Google Scholar
• Humphreys DT, Westman BJ, Martin DI, Preiss T. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci U S A 2005; 102:16961 - 6; http://dx.doi.org/10.1073/pnas.0506482102; PMID: 16287976
   PubMed Web of Science ®Google Scholar
• Mathonnet G, Fabian MR, Svitkin YV, Parsyan A, Huck L, Murata T, et al. MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science 2007; 317:1764 - 7; http://dx.doi.org/10.1126/science.1146067; PMID: 17656684
   PubMed Web of Science ®Google Scholar
• Thermann R, Hentze MW. Drosophila miR2 induces pseudo-polysomes and inhibits translation initiation. Nature 2007; 447:875 - 8; http://dx.doi.org/10.1038/nature05878; PMID: 17507927
   PubMed Web of Science ®Google Scholar
• Wakiyama M, Takimoto K, Ohara O, Yokoyama S. Let-7 microRNA-mediated mRNA deadenylation and translational repression in a mammalian cell-free system. Genes Dev 2007; 21:1857 - 62; http://dx.doi.org/10.1101/gad.1566707; PMID: 17671087
   PubMed Web of Science ®Google Scholar
• Kiriakidou M, Tan GS, Lamprinaki S, De Planell-Saguer M, Nelson PT, Mourelatos Z. An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell 2007; 129:1141 - 51; http://dx.doi.org/10.1016/j.cell.2007.05.016; PMID: 17524464
   PubMed Web of Science ®Google Scholar
• Höck J, Weinmann L, Ender C, Rüdel S, Kremmer E, Raabe M, et al. Proteomic and functional analysis of Argonaute-containing mRNA-protein complexes in human cells. EMBO Rep 2007; 8:1052 - 60; http://dx.doi.org/10.1038/sj.embor.7401088; PMID: 17932509
   PubMed Web of Science ®Google Scholar
• Zhang L, Ding L, Cheung TH, Dong MQ, Chen J, Sewell AK, et al. Systematic identification of C. elegans miRISC proteins, miRNAs, and mRNA targets by their interactions with GW182 proteins AIN-1 and AIN-2. Mol Cell 2007; 28:598 - 613; http://dx.doi.org/10.1016/j.molcel.2007.09.014; PMID: 18042455
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418 - 23; http://dx.doi.org/10.1073/pnas.0932692100; PMID: 12829800
   PubMed Web of Science ®Google Scholar
• Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869 - 74; http://dx.doi.org/10.1073/pnas.191367098; PMID: 11553815
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747 - 52; http://dx.doi.org/10.1038/35021093; PMID: 10963602
   PubMed Web of Science ®Google Scholar
• Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012; 38:698 - 707; http://dx.doi.org/10.1016/j.ctrv.2011.11.005; PMID: 22178455
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101:736 - 50; http://dx.doi.org/10.1093/jnci/djp082; PMID: 19436038
   PubMed Web of Science ®Google Scholar
• Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10:507 - 17; http://dx.doi.org/10.4161/cc.10.3.14754; PMID: 21270527
   PubMed Web of Science ®Google Scholar
• Weigelt B, Mackay A, A’hern R, Natrajan R, Tan DS, Dowsett M, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010; 11:339 - 49; http://dx.doi.org/10.1016/S1470-2045(10)70008-5; PMID: 20181526
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68; http://dx.doi.org/10.1186/bcr2635; PMID: 20813035
   PubMed Web of Science ®Google Scholar
• Bockmeyer CL, Christgen M, Müller M, Fischer S, Ahrens P, Länger F, et al. MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat 2011; 130:735 - 45; http://dx.doi.org/10.1007/s10549-010-1303-3; PMID: 21409395
   PubMed Web of Science ®Google Scholar
• Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009; 11:R27; http://dx.doi.org/10.1186/bcr2257; PMID: 19432961
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-05-1783; PMID: 16103053
   PubMed Web of Science ®Google Scholar
• Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A 2012; 109:3024 - 9; http://dx.doi.org/10.1073/pnas.1200010109; PMID: 22315424
   PubMed Web of Science ®Google Scholar
• Alshatwi AA, Shafi G, Hasan TN, Syed NA, Al-Hazzani AA, Alsaif MA, et al. Differential expression profile and genetic variants of microRNAs sequences in breast cancer patients. PLoS One 2012; 7:e30049; http://dx.doi.org/10.1371/journal.pone.0030049; PMID: 22363415
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta 2012; 413:1058 - 65; http://dx.doi.org/10.1016/j.cca.2012.02.016; PMID: 22387599
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451:147 - 52; http://dx.doi.org/10.1038/nature06487; PMID: 18185580
   PubMed Web of Science ®Google Scholar
• Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14:818 - 29; http://dx.doi.org/10.1016/j.devcel.2008.05.009; PMID: 18539112
   PubMed Web of Science ®Google Scholar
• Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008; 19:294 - 308; http://dx.doi.org/10.1016/j.semcdb.2008.02.001; PMID: 18343170
   PubMed Web of Science ®Google Scholar
• Wang L, Wang J. MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene 2012; 31:2499 - 511; http://dx.doi.org/10.1038/onc.2011.444; PMID: 21963843
   PubMed Web of Science ®Google Scholar
• Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247 - 56; PMID: 20173740
   PubMed Web of Science ®Google Scholar
• Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449:682 - 8; http://dx.doi.org/10.1038/nature06174; PMID: 17898713
   PubMed Web of Science ®Google Scholar
• Moriarty CH, Pursell B, Mercurio AM. miR-10b targets Tiam1: implications for Rac activation and carcinoma migration. J Biol Chem 2010; 285:20541 - 6; http://dx.doi.org/10.1074/jbc.M110.121012; PMID: 20444703
   PubMed Web of Science ®Google Scholar
• Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26:2799 - 803; http://dx.doi.org/10.1038/sj.onc.1210083; PMID: 17072344
   PubMed Web of Science ®Google Scholar
• Song B, Wang C, Liu J, Wang X, Lv L, Wei L, et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 2010; 29:29; http://dx.doi.org/10.1186/1756-9966-29-29; PMID: 20346171
   PubMed Web of Science ®Google Scholar
• Connolly EC, Van Doorslaer K, Rogler LE, Rogler CE. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol Cancer Res 2010; 8:691 - 700; http://dx.doi.org/10.1158/1541-7786.MCR-09-0465; PMID: 20460403
   PubMed Web of Science ®Google Scholar
• Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008; 27:4373 - 9; http://dx.doi.org/10.1038/onc.2008.72; PMID: 18372920
   PubMed Web of Science ®Google Scholar
• Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007; 282:14328 - 36; http://dx.doi.org/10.1074/jbc.M611393200; PMID: 17363372
   PubMed Web of Science ®Google Scholar
• Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008; 18:350 - 9; http://dx.doi.org/10.1038/cr.2008.24; PMID: 18270520
   PubMed Web of Science ®Google Scholar
• Qi L, Bart J, Tan LP, Platteel I, Sluis Tv, Huitema S, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 2009; 9:163; http://dx.doi.org/10.1186/1471-2407-9-163; PMID: 19473551
   PubMed Web of Science ®Google Scholar
• Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009; 10:400 - 5; http://dx.doi.org/10.1038/embor.2009.9; PMID: 19247375
   PubMed Web of Science ®Google Scholar
• Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008; 28:6773 - 84; http://dx.doi.org/10.1128/MCB.00941-08; PMID: 18794355
   PubMed Web of Science ®Google Scholar
• Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10:202 - 10; http://dx.doi.org/10.1038/ncb1681; PMID: 18193036
   PubMed Web of Science ®Google Scholar
• Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10:202 - 10; http://dx.doi.org/10.1038/ncb1681; PMID: 18193036
   PubMed Web of Science ®Google Scholar
• Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 2008; 105:13021 - 6; http://dx.doi.org/10.1073/pnas.0803304105; PMID: 18755890
   PubMed Web of Science ®Google Scholar
• Reddy SD, Ohshiro K, Rayala SK, Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 2008; 68:8195 - 200; http://dx.doi.org/10.1158/0008-5472.CAN-08-2103; PMID: 18922890
   PubMed Web of Science ®Google Scholar
• Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009; 284:5731 - 41; http://dx.doi.org/10.1074/jbc.M804280200; PMID: 19073608
   PubMed Web of Science ®Google Scholar
• Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A 2010; 107:8231 - 6; http://dx.doi.org/10.1073/pnas.1002080107; PMID: 20406904
   PubMed Web of Science ®Google Scholar
• Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 2008; 182:509 - 17; http://dx.doi.org/10.1083/jcb.200801079; PMID: 18695042
   PubMed Web of Science ®Google Scholar
• Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, et al. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol 2011; 193:409 - 24; http://dx.doi.org/10.1083/jcb.201010100; PMID: 21502362
   PubMed Web of Science ®Google Scholar
• Patel JB, Appaiah HN, Burnett RM, Bhat-Nakshatri P, Wang G, Mehta R, et al. Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene 2011; 30:1290 - 301; http://dx.doi.org/10.1038/onc.2010.510; PMID: 21057539
   PubMed Web of Science ®Google Scholar
• Pandey DP, Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 2009; 29:3783 - 90; http://dx.doi.org/10.1128/MCB.01875-08; PMID: 19414598
   PubMed Web of Science ®Google Scholar
• Wu F, Zhu S, Ding Y, Beck WT, Mo YY. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 2009; 15:1550 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-08-0820; PMID: 19223510
   PubMed Web of Science ®Google Scholar
• Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010; 29:4194 - 204; http://dx.doi.org/10.1038/onc.2010.167; PMID: 20498642
   PubMed Web of Science ®Google Scholar
• Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137:1032 - 46; http://dx.doi.org/10.1016/j.cell.2009.03.047; PMID: 19524507
   PubMed Web of Science ®Google Scholar
• Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 2010; 70:5147 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-10-0410; PMID: 20530680
   PubMed Web of Science ®Google Scholar
• Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA. Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 2009; 23:2592 - 7; http://dx.doi.org/10.1101/gad.1832709; PMID: 19875476
   PubMed Web of Science ®Google Scholar
• Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451:147 - 52; http://dx.doi.org/10.1038/nature06487; PMID: 18185580
   PubMed Web of Science ®Google Scholar
• Sempere LF, Preis M, Yezefski T, Ouyang H, Suriawinata AA, Silahtaroglu A, et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 2010; 16:4246 - 55; http://dx.doi.org/10.1158/1078-0432.CCR-10-1152; PMID: 20682703
   PubMed Web of Science ®Google Scholar
• Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, Gregory LA, et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 2011; 71:1550 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-10-2372; PMID: 21343399
   PubMed Web of Science ®Google Scholar
• Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS. Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene 2009; 28:4272 - 83; http://dx.doi.org/10.1038/onc.2009.278; PMID: 19767772
   PubMed Web of Science ®Google Scholar
• Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105:1516 - 21; http://dx.doi.org/10.1073/pnas.0707493105; PMID: 18227515
   PubMed Web of Science ®Google Scholar
• Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15:272 - 84; http://dx.doi.org/10.1016/j.devcel.2008.07.008; PMID: 18694566
   PubMed Web of Science ®Google Scholar
• Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 2010; 17:246 - 54; http://dx.doi.org/10.1038/cdd.2009.117; PMID: 19730444
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 2009; 106:3207 - 12; http://dx.doi.org/10.1073/pnas.0808042106; PMID: 19202062
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70:378 - 87; http://dx.doi.org/10.1158/0008-5472.CAN-09-2021; PMID: 19996288
   PubMed Web of Science ®Google Scholar
• Götte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010; 29:6569 - 80; http://dx.doi.org/10.1038/onc.2010.386; PMID: 20818426
   PubMed Web of Science ®Google Scholar
• Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009; 69:1279 - 83; http://dx.doi.org/10.1158/0008-5472.CAN-08-3559; PMID: 19190326
   PubMed Web of Science ®Google Scholar
• Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008; 27:5643 - 7; http://dx.doi.org/10.1038/onc.2008.171; PMID: 18504431
   PubMed Web of Science ®Google Scholar
• Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009; 28:3937 - 48; http://dx.doi.org/10.1038/onc.2009.245; PMID: 19701247
   PubMed Web of Science ®Google Scholar
• Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009; 19:439 - 48; http://dx.doi.org/10.1038/cr.2009.18; PMID: 19238171
   PubMed Web of Science ®Google Scholar
• Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69:2195 - 200; http://dx.doi.org/10.1158/0008-5472.CAN-08-2920; PMID: 19276373
   PubMed Web of Science ®Google Scholar
• Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 2009; 28:3926 - 36; http://dx.doi.org/10.1038/onc.2009.241; PMID: 19684618
   PubMed Web of Science ®Google Scholar
• Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 2010; 102:706 - 21; http://dx.doi.org/10.1093/jnci/djq102; PMID: 20388878
   PubMed Web of Science ®Google Scholar
• Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 2009; 284:31921 - 7; http://dx.doi.org/10.1074/jbc.M109.046862; PMID: 19723635
   PubMed Web of Science ®Google Scholar
• Edmonds MD, Hurst DR, Vaidya KS, Stafford LJ, Chen D, Welch DR. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer 2009; 125:1778 - 85; http://dx.doi.org/10.1002/ijc.24616; PMID: 19585508
   PubMed Web of Science ®Google Scholar
• Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, et al. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ 2011; 18:16 - 25; http://dx.doi.org/10.1038/cdd.2010.103; PMID: 20798686
   PubMed Web of Science ®Google Scholar
• Vetter G, Saumet A, Moes M, Vallar L, Le Béchec A, Laurini C, et al. miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene 2010; 29:4436 - 48; http://dx.doi.org/10.1038/onc.2010.181; PMID: 20543867
   PubMed Web of Science ®Google Scholar
• Reddy SD, Pakala SB, Ohshiro K, Rayala SK, Kumar R. MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Res 2009; 69:5639 - 42; http://dx.doi.org/10.1158/0008-5472.CAN-09-0898; PMID: 19584269
   PubMed Web of Science ®Google Scholar
• Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131:1109 - 23; http://dx.doi.org/10.1016/j.cell.2007.10.054; PMID: 18083101
   PubMed Web of Science ®Google Scholar
• Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 2009; 28:347 - 58; http://dx.doi.org/10.1038/emboj.2008.294; PMID: 19153603
   PubMed Web of Science ®Google Scholar
• Cabodi S, Taverna D. Interfering with inflammation: a new strategy to block breast cancer self-renewal and progression?. Breast Cancer Res 2010; 12:305; http://dx.doi.org/10.1186/bcr2563; PMID: 20459595
   PubMed Web of Science ®Google Scholar
• Reddy SD, Ohshiro K, Rayala SK, Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 2008; 68:8195 - 200; http://dx.doi.org/10.1158/0008-5472.CAN-08-2103; PMID: 18922890
   PubMed Web of Science ®Google Scholar
• Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004; 145:5439 - 47; http://dx.doi.org/10.1210/en.2004-0959; PMID: 15331580
   PubMed Web of Science ®Google Scholar
• Smalley M, Piggott L, Clarkson R. Breast cancer stem cells: Obstacles to therapy. Cancer Lett 2012; http://dx.doi.org/10.1016/j.canlet.2012.04.023; PMID: 22554712
   PubMed Web of Science ®Google Scholar
• McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol 2010; 4:404 - 19; http://dx.doi.org/10.1016/j.molonc.2010.06.005; PMID: 20599450
   PubMed Web of Science ®Google Scholar
• Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138:592 - 603; http://dx.doi.org/10.1016/j.cell.2009.07.011; PMID: 19665978
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555 - 67; http://dx.doi.org/10.1016/j.stem.2007.08.014; PMID: 18371393
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang D, Zhang C, Zhang S, Wang Z, Qu C, et al. A microRNA expression signature characterizing the properties of tumor-initiating cells for breast cancer. Oncol Lett 2012; 3:119 - 24; PMID: 22740866
   PubMed Web of Science ®Google Scholar
• Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131:1109 - 23; http://dx.doi.org/10.1016/j.cell.2007.10.054; PMID: 18083101
   PubMed Web of Science ®Google Scholar
• Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13:317 - 23; http://dx.doi.org/10.1038/ncb2173; PMID: 21336307
   PubMed Web of Science ®Google Scholar
• Han M, Wang Y, Liu M, Bi X, Bao J, Zeng N, et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci 2012; 103:1058 - 64; http://dx.doi.org/10.1111/j.1349-7006.2012.02281.x; PMID: 22435731
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, et al. Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011; 30:1470 - 80; http://dx.doi.org/10.1038/onc.2010.531; PMID: 21102523
   PubMed Web of Science ®Google Scholar
• Hwang-Verslues WW, Chang PH, Wei PC, Yang CY, Huang CK, Kuo WH, et al. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 2011; 30:2463 - 74; http://dx.doi.org/10.1038/onc.2010.618; PMID: 21258409
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302:1 - 12; http://dx.doi.org/10.1016/j.ydbio.2006.08.028; PMID: 16989803
   PubMed Web of Science ®Google Scholar
• Lund AH. miR-10 in development and cancer. Cell Death Differ 2010; 17:209 - 14; http://dx.doi.org/10.1038/cdd.2009.58; PMID: 19461655
   PubMed Web of Science ®Google Scholar
• Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67:2456 - 68; http://dx.doi.org/10.1158/0008-5472.CAN-06-2698; PMID: 17363563
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103:2257 - 61; http://dx.doi.org/10.1073/pnas.0510565103; PMID: 16461460
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111:5078 - 85; http://dx.doi.org/10.1182/blood-2008-01-133355; PMID: 18337557
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006; 103:9136 - 41; http://dx.doi.org/10.1073/pnas.0508889103; PMID: 16754881
   PubMed Web of Science ®Google Scholar
• Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297:1901 - 8; http://dx.doi.org/10.1001/jama.297.17.1901; PMID: 17473300
   PubMed Web of Science ®Google Scholar
• Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47:1223 - 32; http://dx.doi.org/10.1002/hep.22158; PMID: 18307259
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhao J, Zhang PY, Zhang Y, Sun SY, Yu SY, et al. MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. Med Sci Monit 2012; 18:BR299 - 308; PMID: 22847191
   PubMed Web of Science ®Google Scholar
• Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol 2006; 16:522 - 9; http://dx.doi.org/10.1016/j.tcb.2006.08.006; PMID: 16949823
   PubMed Web of Science ®Google Scholar
• Minard ME, Ellis LM, Gallick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis 2006; 23:301 - 13; http://dx.doi.org/10.1007/s10585-006-9040-z; PMID: 17086355
   PubMed Web of Science ®Google Scholar
• Gee HE, Camps C, Buffa FM, Colella S, Sheldon H, Gleadle JM, et al. MicroRNA-10b and breast cancer metastasis. Nature 2008; 455:E8 - 9, author reply E9; http://dx.doi.org/10.1038/nature07362; PMID: 18948893
   PubMed Web of Science ®Google Scholar
• Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z, et al. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Cell Biochem 2012; 363:427 - 36; http://dx.doi.org/10.1007/s11010-011-1195-5; PMID: 22187223
   PubMed Web of Science ®Google Scholar
• Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y, et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012; 7:e39520; http://dx.doi.org/10.1371/journal.pone.0039520; PMID: 22761812
   PubMed Web of Science ®Google Scholar
• Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65:6029 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-05-0137; PMID: 16024602
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-05-1783; PMID: 16103053
   PubMed Web of Science ®Google Scholar
• Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26:2799 - 803; http://dx.doi.org/10.1038/sj.onc.1210083; PMID: 17072344
   PubMed Web of Science ®Google Scholar
• Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477:267 - 83; http://dx.doi.org/10.1016/S0167-4838(99)00279-4; PMID: 10708863
   PubMed Web of Science ®Google Scholar
• Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13:283 - 96; PMID: 22473468
   PubMed Web of Science ®Google Scholar
• Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J Cell Physiol 2006; 209:617 - 24; http://dx.doi.org/10.1002/jcp.20782; PMID: 17001697
   PubMed Web of Science ®Google Scholar
• Huang GL, Zhang XH, Guo GL, Huang KT, Yang KY, Shen X, et al. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009; 21:673 - 9; PMID: 19212625
   PubMed Web of Science ®Google Scholar
• Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14:2348 - 60; http://dx.doi.org/10.1261/rna.1034808; PMID: 18812439
   PubMed Web of Science ®Google Scholar
• Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 2009; 117:131 - 40; http://dx.doi.org/10.1007/s10549-008-0219-7; PMID: 18932017
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435:828 - 33; http://dx.doi.org/10.1038/nature03552; PMID: 15944707
   PubMed Web of Science ®Google Scholar
• Fassina A, Marino F, Siri M, Zambello R, Ventura L, Fassan M, et al. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest 2012; 92:1574 - 82; http://dx.doi.org/10.1038/labinvest.2012.129; PMID: 22964854
   PubMed Web of Science ®Google Scholar
• Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004; 64:3087 - 95; http://dx.doi.org/10.1158/0008-5472.CAN-03-3773; PMID: 15126345
   PubMed Web of Science ®Google Scholar
• Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65:9628 - 32; http://dx.doi.org/10.1158/0008-5472.CAN-05-2352; PMID: 16266980
   PubMed Web of Science ®Google Scholar
• Li H, Bian C, Liao L, Li J, Zhao RC. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat 2011; 126:565 - 75; http://dx.doi.org/10.1007/s10549-010-0954-4; PMID: 20505989
   PubMed Web of Science ®Google Scholar
• Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403:901 - 6; http://dx.doi.org/10.1038/35002607; PMID: 10706289
   PubMed Web of Science ®Google Scholar
• Wang X, Cao L, Wang Y, Wang X, Liu N, You Y. Regulation of let-7 and its target oncogenes (Review). [Review] Oncol Lett 2012; 3:955 - 60; PMID: 22783372
   PubMed Web of Science ®Google Scholar
• Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64:3753 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-04-0637; PMID: 15172979
   PubMed Web of Science ®Google Scholar
• Zhang HH, Wang XJ, Li GX, Yang E, Yang NM. Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol 2007; 13:2883 - 8; PMID: 17569129
   PubMed Web of Science ®Google Scholar
• Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006; 29:903 - 6; http://dx.doi.org/10.1248/bpb.29.903; PMID: 16651716
   PubMed Web of Science ®Google Scholar
• Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007; 67:9762 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-07-2462; PMID: 17942906
   PubMed Web of Science ®Google Scholar
• Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67:11612 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-07-5019; PMID: 18089790
   PubMed Web of Science ®Google Scholar
• Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22:894 - 907; http://dx.doi.org/10.1101/gad.1640608; PMID: 18381893
   PubMed Web of Science ®Google Scholar
• Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283:14910 - 4; http://dx.doi.org/10.1074/jbc.C800074200; PMID: 18411277
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593 - 601; http://dx.doi.org/10.1038/ncb1722; PMID: 18376396
   PubMed Web of Science ®Google Scholar
• Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, et al. MicroRNA-200c Represses Migration and Invasion of Breast Cancer Cells by Targeting Actin-Regulatory Proteins FHOD1 and PPM1F. Mol Cell Biol 2011; 32:633 - 51; http://dx.doi.org/10.1128/MCB.06212-11; PMID: 22144583
   PubMed Web of Science ®Google Scholar
• Chen J, Tian W, Cai H, He H, Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 2011; 29:2527 - 34; http://dx.doi.org/10.1007/s12032-011-0117-4; PMID: 22101791
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010; 39:761 - 72; http://dx.doi.org/10.1016/j.molcel.2010.08.013; PMID: 20832727
   PubMed Web of Science ®Google Scholar
• Uhlmann S, Zhang JD, Schwäger A, Mannsperger H, Riazalhosseini Y, Burmester S, et al. miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 2010; 29:4297 - 306; http://dx.doi.org/10.1038/onc.2010.201; PMID: 20514023
   PubMed Web of Science ®Google Scholar
• Schickel R, Park SM, Murmann AE, Peter ME. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010; 38:908 - 15; http://dx.doi.org/10.1016/j.molcel.2010.05.018; PMID: 20620960
   PubMed Web of Science ®Google Scholar
• Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22:894 - 907; http://dx.doi.org/10.1101/gad.1640608; PMID: 18381893
   PubMed Web of Science ®Google Scholar
• Li S, Wang Q, Wang Y, Chen X, Wang Z. PLC-gamma1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migration. Mol Endocrinol 2009; 23:901 - 13; http://dx.doi.org/10.1210/me.2008-0368; PMID: 19264842
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2009; 2:ra62; http://dx.doi.org/10.1126/scisignal.2000356; PMID: 19825827
   PubMed Web of Science ®Google Scholar
• Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009; 23:2140 - 51; http://dx.doi.org/10.1101/gad.1820209; PMID: 19759262
   PubMed Web of Science ®Google Scholar
• Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9:582 - 9; http://dx.doi.org/10.1038/embor.2008.74; PMID: 18483486
   PubMed Web of Science ®Google Scholar
• Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68:7846 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-08-1942; PMID: 18829540
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009; 4:e7181; http://dx.doi.org/10.1371/journal.pone.0007181; PMID: 19787069
   PubMed Web of Science ®Google Scholar
• Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17:1101 - 8; http://dx.doi.org/10.1038/nm.2401; PMID: 21822286
   PubMed Web of Science ®Google Scholar
• Jelena R, Apostolos Z, Thomas V, Maria K, Demetrios AS, Efstathios NS. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10:10 - 2; PMID: 21191182
   PubMed Web of Science ®Google Scholar
• Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67:11612 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-07-5019; PMID: 18089790
   PubMed Web of Science ®Google Scholar
• Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 2012; 6:458 - 72; http://dx.doi.org/10.1016/j.molonc.2012.03.003; PMID: 22578566
   PubMed Web of Science ®Google Scholar
• Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 2010; 17:246 - 54; http://dx.doi.org/10.1038/cdd.2009.117; PMID: 19730444
   PubMed Web of Science ®Google Scholar
• Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, et al. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 2011; 155:427 - 34; http://dx.doi.org/10.1016/j.jconrel.2011.06.026; PMID: 21723890
   PubMed Web of Science ®Google Scholar
• Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ, et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 2012; 11:2137 - 45; http://dx.doi.org/10.4161/cc.20598; PMID: 22592534
   PubMed Web of Science ®Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9:105 - 27; http://dx.doi.org/10.2217/14622416.9.1.105; PMID: 18154452
   PubMed Web of Science ®Google Scholar
• Baker EK, El-Osta A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 2003; 290:177 - 94; http://dx.doi.org/10.1016/S0014-4827(03)00342-2; PMID: 14567978
   PubMed Web of Science ®Google Scholar
• Idelman G, Jacobson EM, Tuttle TR, Ben-Jonathan N. Lactogens and estrogens in breast cancer chemoresistance. Expert Rev Endocrinol Metab 2011; 6:411 - 22; http://dx.doi.org/10.1586/eem.11.19; PMID: 21731573
   PubMedGoogle Scholar
• Wilson T, Longley D, Johnston P.. Chemoresistance in solid tumours. Ann Onc 2006; 17:Suppl 10:x315 - 24
   Web of Science ®Google Scholar
• Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995; 51:167 - 223; http://dx.doi.org/10.1016/S0079-6603(08)60879-X; PMID: 7659775
   PubMed Web of Science ®Google Scholar
• Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7:2152 - 9; http://dx.doi.org/10.1158/1535-7163.MCT-08-0021; PMID: 18645025
   PubMed Web of Science ®Google Scholar
• Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 2012; 180:2490 - 503; http://dx.doi.org/10.1016/j.ajpath.2012.02.024; PMID: 22521303
   PubMed Web of Science ®Google Scholar
• Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010; 79:817 - 24; http://dx.doi.org/10.1016/j.bcp.2009.10.017; PMID: 19883630
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010; 127:1785 - 94; http://dx.doi.org/10.1002/ijc.25191; PMID: 20099276
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983 - 8; http://dx.doi.org/10.1073/pnas.0530291100; PMID: 12629218
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101:14228 - 33; http://dx.doi.org/10.1073/pnas.0400067101; PMID: 15381773
   PubMed Web of Science ®Google Scholar
• Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283:29897 - 903; http://dx.doi.org/10.1074/jbc.M804612200; PMID: 18708351
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283:31079 - 86; http://dx.doi.org/10.1074/jbc.M806041200; PMID: 18790736
   PubMed Web of Science ®Google Scholar
• Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011; 30:1082 - 97; http://dx.doi.org/10.1038/onc.2010.487; PMID: 21057537
   PubMed Web of Science ®Google Scholar
• Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009; 75:1374 - 9; http://dx.doi.org/10.1124/mol.108.054163; PMID: 19270061
   PubMed Web of Science ®Google Scholar
• Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010; 79:817 - 24; http://dx.doi.org/10.1016/j.bcp.2009.10.017; PMID: 19883630
   PubMed Web of Science ®Google Scholar
• Masri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat 2010; 124:89 - 99; http://dx.doi.org/10.1007/s10549-009-0716-3; PMID: 20054641
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010; 127:1785 - 94; http://dx.doi.org/10.1002/ijc.25191; PMID: 20099276
   PubMed Web of Science ®Google Scholar
• Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010; 285:17869 - 79; http://dx.doi.org/10.1074/jbc.M110.101055; PMID: 20371610
   PubMed Web of Science ®Google Scholar
• Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010; 285:21496 - 507; http://dx.doi.org/10.1074/jbc.M109.083337; PMID: 20460378
   PubMed Web of Science ®Google Scholar
• Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 2010; 9:317; http://dx.doi.org/10.1186/1476-4598-9-317; PMID: 21172025
   PubMed Web of Science ®Google Scholar
• Kastl L, Brown I, Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 2012; 131:445 - 54; http://dx.doi.org/10.1007/s10549-011-1424-3; PMID: 21399894
   PubMed Web of Science ®Google Scholar
• Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, et al. Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer. J Biol Chem 2011; 287:286 - 98; PMID: 22069308
   PubMed Web of Science ®Google Scholar
• Wang ZX, Lu BB, Wang H, Cheng ZX, Yin YM. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res 2011; 42:281 - 90; http://dx.doi.org/10.1016/j.arcmed.2011.06.008; PMID: 21820606
   PubMed Web of Science ®Google Scholar
• Liang Z, Li Y, Huang K, Wagar N, Shim H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 2011; 28:3091 - 100; http://dx.doi.org/10.1007/s11095-011-0570-y; PMID: 21853360
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 2011; 17:7105 - 15; http://dx.doi.org/10.1158/1078-0432.CCR-11-0071; PMID: 21953503
   PubMed Web of Science ®Google Scholar
• Chen J, Tian W, Cai H, He H, Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 2012; 29:2527 - 34; http://dx.doi.org/10.1007/s12032-011-0117-4; PMID: 22101791
   PubMed Web of Science ®Google Scholar
• Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. Genes Cancer 2011; 2:720 - 7; http://dx.doi.org/10.1177/1947601911425832; PMID: 22207897
   PubMedGoogle Scholar
• Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 2012; 180:2490 - 503; http://dx.doi.org/10.1016/j.ajpath.2012.02.024; PMID: 22521303
   PubMed Web of Science ®Google Scholar